<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30124121</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1477-092X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>19</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</Title>                <ISOAbbreviation>J Oncol Pharm Pract</ISOAbbreviation>            </Journal>            <ArticleTitle>Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade.</ArticleTitle>            <Pagination>                <MedlinePgn>1078155218792672</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1078155218792672</ELocationID>            <Abstract>                <AbstractText>Paraneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus-myoclonus-ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%-25% of breast cancer and is associated with poor prognosis. There are a few reports of paraneoplastic neurological syndrome associated with HER2-positive breast cancer in the literature, of which most are anti-Yo-associated paraneoplastic neurological syndrome. We present herein the case of a female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus-myoclonus paraneoplastic neurological syndrome. Following the diagnosis of paraneoplastic syndrome, chemotherapy with dual HER2 blockade and immunomodulating treatment including intravenous immunoglobulin and oral prednisolone were administered. Although the patient was negative for serum anti-Ri antibodies, there was partial clinical improvement and her neurological deficit persisted. To our knowledge, this is the first case report of female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus-myoclonus paraneoplastic neurological syndrome and treated with dual HER2 blockade.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Olmez</LastName>                    <ForeName>Omer Fatih</ForeName>                    <Initials>OF</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kinikoglu</LastName>                    <ForeName>Oguzcan</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>2 Deparment of Internal Medicine, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yilmaz</LastName>                    <ForeName>Nesrin Helvacı</ForeName>                    <Initials>NH</Initials>                    <AffiliationInfo>                        <Affiliation>3 Department of Neurology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bilici</LastName>                    <ForeName>Ahmet</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cubukcu</LastName>                    <ForeName>Erdem</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>4 Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Seker</LastName>                    <ForeName>Mehmet</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>5 Department of Radiology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cakir</LastName>                    <ForeName>Tansel</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>6 Department of Nuclear Medicine, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yildiz</LastName>                    <ForeName>Ozcan</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hamdard</LastName>                    <ForeName>Jamshid</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>2 Deparment of Internal Medicine, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>19</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Oncol Pharm Pract</MedlineTA>            <NlmUniqueID>9511372</NlmUniqueID>            <ISSNLinking>1078-1552</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HER2 blockade</Keyword>            <Keyword MajorTopicYN="N">Paraneoplastic neurological syndrome</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">opsoclonus–myoclonus syndrome</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30124121</ArticleId>            <ArticleId IdType="doi">10.1177/1078155218792672</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>